Comparison between talazoparib and conventional chemotherapy in the treatment of HER2-positive breast cancer patients: A retrospective study

BACKGROUND: The benefits of talazoparib compared with conventional chemotherapy in HER2-negative advanced breast cancer (ABC) remain unclear. METHODS: Patients older than 18 years, with a deleterious germline BRCA1/2 (gBRCA1/2) mutated, metastatic, or locally advanced and HER2-positive breast cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ning, Yu, Xiaopeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422399/
https://www.ncbi.nlm.nih.gov/pubmed/36045677
http://dx.doi.org/10.3389/fimmu.2022.901636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422399/
https://www.ncbi.nlm.nih.gov/pubmed/36045677
http://dx.doi.org/10.3389/fimmu.2022.901636

Ejemplares similares